Goldman Sachs upgraded ResMed (NYSE: RMD) from Buy to Conviction Buy. Analyst Ian Abbott sees 14% potential return.

"We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE